Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
Avenue Therapeutics, Inc. logo

NASDAQ · ATXI

Avenue Therapeutics, Inc.

Healthcare · Biotechnology

$0.43

Up+$0.00 (+0.00%)

Updated Oct 10, 2026, 3:05 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.07M
P/E ratio
2.76
Dividend yield
0.00%
52-week range
— – —
Volume
5.02K
Avg. volume
3.29K

Price performance · ATXI

ATXI price history

1M range · 0 trading sessions · Daily adjusted prices

ATXI does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ATXI news

The latest Smart Investors Daily articles mentioning ATXI.

Stock researchCompany · Overview

ATXI research

Overview

Company profile and research snapshot.

Company profile

AVENUE THERAPEUTICS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
ATXI recent ratings
DateFirmRatingTarget
Dec 11, 2023Maxim GroupBuy—
Apr 3, 2023Aegis CapitalBuy—
May 12, 2020HC Wainwright & Co.Buy—
Jul 13, 2018OppenheimerOutperform—
Jun 25, 2018H.C. WainwrightBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 23, 2026

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke U

globenewswire.com · Nov 6, 2025

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (“Baergic”), today announced that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome”), including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator (PAM). BAER-101 was originally licensed by Baergic from AstraZeneca AB (“AstraZeneca”) and will be referred to as AXS-17 by Axsome going forward.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By